CJC-1295 No DAC + Ipamorelin
Dual-pathway GH-axis blend pairing a short-acting GHRH analogue with a selective ghrelin receptor agonist to model physiologic, pulse-based growth hormone release.
Explore calculators for this blend
Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for CJC-1295 No DAC + Ipamorelin. All values are placeholders and must be aligned with your own research protocol.
Open CJC-1295 No DAC + Ipamorelin →
Research frame & potential applications
This combination leverages CJC‑1295 (No DAC) to potentiate endogenous GHRH signalling and Ipamorelin to activate GHSR1a, amplifying pituitary GH pulses while preserving circadian rhythm.
It is used in research to study GH-axis synergy, IGF‑1 generation, recovery and body composition under a more physiological, spike-based GH pattern compared with long-acting DAC-only regimens.
Research areas & putative benefits
How the No-DAC CJC + Ipamorelin stack is positioned in GH-axis research.
- Mapping pulse-based GH secretion and IGF‑1 responses under combined GHRH and ghrelin-pathway drive.
- Exploring tissue repair, recovery and body-composition shifts with more physiological GH patterns than continuous long-acting analogues.
- Comparing pituitary desensitisation, receptor down-regulation and feedback versus DAC-only CJC‑1295 or GHS-only regimens.
- Characterising second-messenger integration when GHRH and GHSR GPCR pathways are co-activated in somatotrophs.
Mechanism stack
How the two components interact at the pituitary and hypothalamic level.
CJC-1295 No DAC arm
GHRH receptor stimulation
CJC‑1295 No DAC mimics endogenous growth hormone–releasing hormone, binding GHRH receptors on pituitary somatotrophs to enhance GH synthesis and physiologic pulse frequency with a relatively short active window.
Ipamorelin arm
GHSR1a activation
Ipamorelin selectively activates GHSR1a, boosting GH pulse amplitude via ghrelin-like calcium signalling without significantly raising ACTH or cortisol at typical research doses.
Synergy
Amplitude × frequency
Co-administration allows CJC‑1295 No DAC to prime somatotroph GH content and pulse timing, while Ipamorelin spikes pulse height, yielding higher total GH and IGF‑1 exposure with preserved circadian patterning.
Desensitisation profile
Lower saturation vs DAC
Without a long-acting DAC tail, CJC‑1295 No DAC produces shorter receptor engagement, potentially reducing chronic receptor saturation and desensitisation risk compared with DAC-only long-acting GH secretagogues.
Evidence snapshot
Key findings from dual-pathway GH-stimulation work.
| Model / context | Observation | Relevance |
|---|---|---|
|
Pituitary cell assays
In vitro
|
Combined GHRH analogue and GHSR agonist exposure increases GH release more than either alone, highlighting convergent but distinct GPCR pathways. | Supports the mechanistic basis for stacking CJC‑1295 No DAC with Ipamorelin in GH research. |
|
Human blend pilot data
Translational
|
Small studies and RUO reports show increased serum GH and IGF‑1 with maintained night-time pulse structure when the combo is used in evening protocols. | Aligns with the goal of mimicking physiologic GH rhythm rather than flattening it with continuous signalling. |
|
DAC vs No-DAC comparisons
Pharmacology
|
CJC‑1295 with DAC exhibits multi-day half-life and continuous receptor stimulation, whereas No DAC is shorter-acting and more compatible with discrete pulse timing. | Explains why No-DAC forms are preferentially stacked with GHSR agonists like Ipamorelin. |
|
Recovery & body composition
Exploratory
|
Research models report improvements in surrogate markers of recovery and lean-body parameters, though controlled long-term outcome data remain limited. | Underlines a research-only framing, not a validated therapeutic protocol. |
Risk frame & unknowns
Caveats around stacked GH-axis stimulation.
Important research caveats
- Dual stimulation increases total GH and IGF‑1 exposure, potentially amplifying long-term risks associated with GH excess (cardiac, metabolic, oncogenic).
- Validated, long-term human safety data for the fixed combo are sparse; most evidence is short-term and surrogate-based.
- Poorly timed dosing can blunt natural GH rhythm or cause receptor desensitisation, undermining the “physiologic” intent.
- Unregulated formulations may differ in ratio, purity and actual content, complicating reproducibility and safety assessments.
This dossier summarizes mechanistic and early translational findings on the CJC‑1295 No DAC + Ipamorelin blend for scientific and educational purposes only.
It does not provide medical advice, treatment guidance or dosing recommendations.